Breast cancer and HSP90 inhibitors: Is there a role beyond the HER2-positive subtype?
Open Access
- 31 August 2012
- journal article
- research article
- Published by Elsevier BV in The Breast
- Vol. 21 (4), 604-607
- https://doi.org/10.1016/j.breast.2012.04.002
Abstract
No abstract availableKeywords
This publication has 43 references indexed in Scilit:
- Effective Targeting of Triple-Negative Breast Cancer Cells by PF-4942847, a Novel Oral Inhibitor of Hsp 90Clinical Cancer Research, 2011
- Antitumor Activity of the Hsp90 Inhibitor IPI-504 in HER2-Positive Trastuzumab-Resistant Breast CancerMolecular Cancer Therapeutics, 2011
- Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine ResistanceCancer Research, 2009
- Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growthOncogene, 2009
- PIK3CA expression in invasive breast cancer: a biomarker of poor prognosisBreast Cancer Research and Treatment, 2009
- Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer modelsProceedings of the National Academy of Sciences of the United States of America, 2009
- NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer modelsBreast Cancer Research, 2008
- Discovery of Quinolinediones Exhibiting a Heat Shock Response and Angiogenesis InhibitionJournal of Medicinal Chemistry, 2008
- Sensitivity of epidermal growth factor receptor and ErbB2 exon 20 insertion mutants to Hsp90 inhibitionBritish Journal of Cancer, 2007
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001